Over the last few years, Cytori Therapeutics has had a very poor record of delivering on its own words, specifically as they relate to the timing of partnerships, the need for additional capital and an expected EU approval for the treatment of No Option CMI patients.
http://seekingalpha.com/article/1221811-cytori-s-eu-approval-for-intravase-intentionally-downplayed?source=feed
http://seekingalpha.com/article/1221811-cytori-s-eu-approval-for-intravase-intentionally-downplayed?source=feed
No comments:
Post a Comment